Journal of Medical Economics Article Demonstrates Economic Benefits of Cardiovascular Systems Orbital Atherectomy in the Treatment of Peripheral Artery Disease

PerkinElmer to Acquire In-Vitro Diagnostics Company Immunodiagnostic Systems Holdings PLC

IDS’s portfolio and expertise will seamlessly integrate within EUROIMMUN, a PerkinElmer company since 2017.

Precision Spine Reaches Milestone with the Reform® Modular Pedicle Screw System

The Reform® Modular Pedicle Screw System provides surgeons with increased flexibility, versatility, and visibility to meet the varying requirements of degenerative and trauma procedures.

Cardiovascular Systems, a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that a new article published in the Journal of Medical Economicsreviews the two-year PAD-related health care costs of patients enrolled in the LIBERTY 360° trial.

LIBERTY 360° represents the largest, contemporary real-world experience with various endovascular strategies across the full range of Rutherford Class (RC) patients, including those with critical limb ischemia, the most compromised RC6 patients.

In the article, “Two-year PAD-related health care costs in patients undergoing lower extremity endovascular revascularization: results from the LIBERTY 360° trial” by Elizabeth A. Magnuson, et al., the authors note that among patients with symptomatic lower extremity PAD undergoing endovascular revascularization, initial treatment costs and total 2-year costs varied significantly according to clinical and lesion-level characteristics, as well as symptom burden.

Said Scott Ward, CSI’s Chairman, President and Chief Executive Officer, “Data from the LIBERTY 360° study revealed high freedom from major amputation out to three years (RC2-3, 98.5%; RC4-5, 94.0%; and RC6, 79.9%). And the orbital atherectomy sub analysis of this data indicated high freedom from major amputation (RC2-3, 100%; RC4-5, 95.3%; and RC6, 88.6%) with no additional amputations reported after the two-year visit. These data are especially compelling in the context of cost analyses showing that the durable patient outcomes from the use of orbital atherectomy resulted in lower mean cumulative PAD-related costs one- and two-years after the procedure.”

LIBERTY 360° (OAS RC2-6) 2-Year Costs

Orbital atherectomy (RC2-6; N=503) mean index procedure cost was $11,729 and by two-years the mean costs were $29,474, numerically lower than the overall LIBERTY (RC2-6; N=1189) mean two-year cost of $30,491.

PAD-related costs ($) up to 2 years following the index procedure

All Patients

Any Orbital
Atherectomy

All Patients

Any Orbital
Atherectomy

Index Hospitalization

11,621

(11,189 to 12,081)

11,729

(11,165 to 12,443)

Years 1+2 follow-up

18,870

(17,046 to 20,802)

17,745

(15,113 to 20,835)

Year 1 follow-up

11,741

(10,597 to 12,974)

10,976

(9,344 to 12,741)

Endovascular procedures

7,476

(6,730 to 8,263)

6,911

(5,758 to 8,127)

Endovascular procedures

11,465

(10,321 to 12,688)

10,806

8,944 to 12,916)

Surgical procedures

1,625

1,218 to 2,041)

1,698

(1,096 to 2,384)

Surgical procedures

2,077

(1,616 to 2,569)

1,987

(1,353 to 2,708)

Other PAD hospitalizations

140

(74 to 211)

115

(34 to 231)

Other PAD hospitalizations

193

(113 to 278)

128

(41 to 251)

Outpatient/ chronic care

2,501

(2,011 to 3,000)

2,253

(1,586 to 3,126)

Outpatient/ chronic care

5,134

(4,041 to 6,253)

4,824

(3,272 to 6,791)

Cumulative 1-year

23,362

(22,110 to 24,623)

22,706

(20,998 to 24,627)

Cumulative 2-year

30,491

(28,569 to 32,506)

29,474

(26,655 to 32,665)

Magnuson EA, et al. J Med Econ. 2021 April 18:1

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles